alosetron has been researched along with Pain in 5 studies
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 320 functional dyspepsia patients received placebo (n=81), or alosetron 0." | 9.09 | A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. ( Dukes, G; Heath, M; Kleoudis, C; Mangel, AW; Perschy, T; Saez, LR; Talley, NJ; Van Zanten, SV, 2001) |
| "Alosetron (Lotronex, GlaxoSmithKline) is a potent and selective 5-HT(3)-receptor antagonist approved by the FDA for the treatment of women with diarrhoea-predominant irritable bowel syndrome (IBS) in whom conventional therapy has failed." | 8.82 | Alosetron and irritable bowel syndrome. ( Bradesi, S; Mayer, EA, 2003) |
| "A total of 320 functional dyspepsia patients received placebo (n=81), or alosetron 0." | 5.09 | A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. ( Dukes, G; Heath, M; Kleoudis, C; Mangel, AW; Perschy, T; Saez, LR; Talley, NJ; Van Zanten, SV, 2001) |
| "Alosetron (Lotronex, GlaxoSmithKline) is a potent and selective 5-HT(3)-receptor antagonist approved by the FDA for the treatment of women with diarrhoea-predominant irritable bowel syndrome (IBS) in whom conventional therapy has failed." | 4.82 | Alosetron and irritable bowel syndrome. ( Bradesi, S; Mayer, EA, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mayer, EA | 1 |
| Bradesi, S | 1 |
| Mori, T | 1 |
| Kawano, K | 1 |
| Shishikura, T | 1 |
| Jones, RH | 1 |
| Holtmann, G | 1 |
| Rodrigo, L | 1 |
| Ehsanullah, RS | 1 |
| Crompton, PM | 1 |
| Jacques, LA | 2 |
| Mills, JG | 2 |
| Bardhan, KD | 1 |
| Bodemar, G | 1 |
| Geldof, H | 1 |
| Schütz, E | 1 |
| Heath, A | 1 |
| Talley, NJ | 1 |
| Van Zanten, SV | 1 |
| Saez, LR | 1 |
| Dukes, G | 1 |
| Perschy, T | 1 |
| Heath, M | 1 |
| Kleoudis, C | 1 |
| Mangel, AW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Investigator Blinded, Controlled Trial to Evaluate the Effectiveness of Dietary Modification in Patients With Functional Dyspepsia[NCT02863822] | 0 participants (Actual) | Interventional | 2016-09-30 | Withdrawn (stopped due to no patients enrolled) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for alosetron and Pain
| Article | Year |
|---|---|
Alosetron and irritable bowel syndrome.
Topics: Carbolines; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Pain; Product Surveillance, P | 2003 |
3 trials available for alosetron and Pain
| Article | Year |
|---|---|
Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
Topics: Adolescent; Adult; Carbolines; Colonic Diseases, Functional; Double-Blind Method; Female; Humans; Pa | 1999 |
A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
Topics: Adolescent; Adult; Aged; Carbolines; Colonic Diseases, Functional; Double-Blind Method; Female; Huma | 2000 |
A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.
Topics: Administration, Oral; Adult; Carbolines; Dose-Response Relationship, Drug; Double-Blind Method; Dysp | 2001 |
1 other study available for alosetron and Pain
| Article | Year |
|---|---|
5-HT3-receptor antagonist inhibits visceral pain differently in chemical and mechanical stimuli in rats.
Topics: Animals; Carbolines; Colon; Disease Models, Animal; Dose-Response Relationship, Drug; Glycerol; Male | 2004 |